Table 2.
Registered COVID-19–BCG vaccine related clinical trials [42]
| No. | Clinical trial | Country | No. of participants |
|---|---|---|---|
| 1 | BCG vaccine for health care workers as defense against COVID 19 (BADAS) | USA | 1.800 |
| 2 | Application of BCG vaccine for immune-prophylaxis among Egyptian healthcare workers during the pandemic of COVID-19 | Egypt | 900 |
| 3 | Reducing health care workers absenteeism in COVID-19 pandemic through BCG vaccine | Netherlands | 1,500 |
| 4 | Using BCG vaccine to protect health care workers in the COVID-19 pandemic | Denmark | 1,500 |
| 5 | BCG vaccination to protect healthcare workers against COVID-19 | Australia | 4,170 |
| 6 | Performance evaluation of BCG vaccination in healthcare personnel to reduce the severity of SARS-COV-2 infection | Colombia | 1,000 |
| 7 | BCG vaccination for healthcare workers in COVID-19 pandemic | South Africa | 500 |
| 8 | Efficacy of BCG vaccination in the prevention of COVID19 via the strengthening of innate immunity in health care workers (COVID-BCG) | France | 1,120 |
| 9 | COVID-19: BCG as therapeutic vaccine, transmission limitation, and immunoglobulin enhancement (BATTLE) | Brazil | 1,000 |
| 10 | BCG vaccine in reducing morbidity and mortality in elderly individuals in COVID-19 hotspots | India | 2,175 |
| 11 | Prevention, efficacy and safety of BCG vaccine in COVID-19 among healthcare workers | Mexico | 908 |
| 12 | Bacillus Calmette-Guérin vaccination to prevent COVID-19 | Greece | 900 |
COVID-19, coronavirus disease 2019; BCG, Bacillus Calmette-Guérin.